Integra LifeSciences Holdings Corporation (NASDAQ:IART)‘s stock had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc. in a research report issued to clients and investors on Monday. They presently have a $60.00 price objective on the life sciences company’s stock. Oppenheimer Holdings, Inc.’s price objective indicates a potential upside of 15.56% from the company’s current price.

IART has been the subject of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Integra LifeSciences Holdings Corporation in a report on Monday, July 10th. ValuEngine cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Zacks Investment Research upgraded Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Raymond James Financial, Inc. upped their price objective on Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. Finally, BidaskClub cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Integra LifeSciences Holdings Corporation has a consensus rating of “Buy” and a consensus price target of $53.54.

Integra LifeSciences Holdings Corporation (NASDAQ IART) traded up 0.39% during trading on Monday, reaching $52.12. The company’s stock had a trading volume of 127,160 shares. The company has a market cap of $4.07 billion, a PE ratio of 63.56 and a beta of 0.73. The stock has a 50-day moving average price of $50.44 and a 200 day moving average price of $48.38. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The business had revenue of $282.16 million during the quarter, compared to analysts’ expectations of $283.58 million. During the same period in the previous year, the business earned $0.40 earnings per share. The firm’s revenue was up 13.2% on a year-over-year basis. On average, analysts expect that Integra LifeSciences Holdings Corporation will post $1.90 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Oppenheimer Holdings, Inc. Reaffirms Buy Rating for Integra LifeSciences Holdings Corporation (IART)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/18/oppenheimer-holdings-inc-reaffirms-buy-rating-for-integra-lifesciences-holdings-corporation-iart.html.

In other news, Director Barbara B. Hill acquired 5,050 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was purchased at an average price of $49.33 per share, for a total transaction of $249,116.50. Following the completion of the transaction, the director now directly owns 44,772 shares in the company, valued at approximately $2,208,602.76. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were purchased at an average price of $49.25 per share, with a total value of $492,500.00. Following the transaction, the director now owns 29,612 shares of the company’s stock, valued at $1,458,391. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 17,550 shares of company stock valued at $864,842. Company insiders own 21.50% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Acrospire Investment Management LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 280.0% during the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares in the last quarter. Riverhead Capital Management LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 49.9% during the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares in the last quarter. LS Investment Advisors LLC grew its position in shares of Integra LifeSciences Holdings Corporation by 90.7% during the first quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock valued at $102,000 after purchasing an additional 1,147 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Integra LifeSciences Holdings Corporation by 223.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after purchasing an additional 1,751 shares in the last quarter. Finally, Turner Investments LLC purchased a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter valued at about $126,000. Hedge funds and other institutional investors own 84.90% of the company’s stock.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Stock Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related stocks with our FREE daily email newsletter.